Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6543753 | 0.72 | MEN1 (0.38) | MEN1KMT2ASLC6A3 | |
| SCHEMBL8485274 | 0.72 | MEN1 (0.36) | MEN1KMT2ASLC6A3 | |
| SCHEMBL8003850 | 0.72 | MEN1 (0.48) | MEN1KMT2ARAB9AL3MBTL1 | |
| SCHEMBL11537124 | 0.71 | MEN1 (0.50) | MEN1KMT2ARAB9A | |
| SCHEMBL1263510 | 0.71 | MEN1 (0.50) | MEN1KMT2ARAB9A | |
| SCHEMBL8484373 | 0.71 | MEN1 (0.38) | MEN1KMT2AKDM4CSLC6A3 | |
| SCHEMBL6952332 | 0.70 | SLC6A3 (0.36) | MEN1KMT2AKDM4CSLC6A3NPC1 | |
| SCHEMBL8316137 | 0.70 | SLC6A3 (0.45) | MEN1KMT2AKDM4CSLC6A3NPC1 | |
| SCHEMBL25176578 | 0.70 | KMT2A (0.44) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL8556420 | 0.69 | MEN1 (0.41) | MEN1KMT2AKDM4CSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5679693-A | TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING THE TACHYKININ SYSTEM | SANOFI (FR) | 1997-10-21 | — | — | US | disclosed |